Compare IBRX & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | OI |
|---|---|---|
| Founded | 2014 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | IBRX | OI |
|---|---|---|
| Price | $2.05 | $15.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $9.71 | ★ $16.29 |
| AVG Volume (30 Days) | ★ 13.6M | 2.3M |
| Earning Date | 11-04-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,555,000.00 | ★ $6,455,000,000.00 |
| Revenue This Year | $667.18 | $1.41 |
| Revenue Next Year | $93.03 | $1.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | N/A |
| 52 Week Low | $1.83 | $9.23 |
| 52 Week High | $4.27 | $16.04 |
| Indicator | IBRX | OI |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 62.59 |
| Support Level | $1.95 | $14.70 |
| Resistance Level | $2.29 | $15.09 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 19.09 | 55.60 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.